FOR IMMEDIATE RELEASE

SALIENT SURGICAL TO INTRODUCE TRANSCOLLATION® TECHNOLOGY TO PROVIDE HEMOSTASIS DURING KIDNEY SURGERIES

PORTSMOUTH, NH—January 21, 2011—Privately-held Salient Surgical Technologies, Inc., today announced that it will be introducing the AQUAMANTYS® bipolar sealer product line to surgeons for use in partial nephrectomy procedures. Salient's AQUAMANTYS System uses TRANSCOLLATION technology, a proprietary combination of radiofrequency energy and saline that enables surgeons to prevent and stop bleeding of soft tissue and bone during surgery and thereby decrease the risk of blood transfusions. This technology has already been used to improve patient care for more than 500,000 patients undergoing orthopaedic reconstruction, spine, brain tumor resection, trauma, and surgical oncology procedures.

Commenting on the clinical value of Salient’s technology for partial nephrectomy procedures, Courtney Phillips, MD, Assistant Professor of Medicine at Mount Sinai Medical School stated, “We have found Salient’s TRANSCOLLATION technology to be tremendously valuable during these procedures. Given the significant amount of blood flow to the kidney, these procedures can potentially result in significant blood loss. We have found that when we apply TRANSCOLLATION technology to the tumor bed after resection, we are able to achieve hemostasis quickly and efficiently. This allows us to get off-clamp faster and supports our efforts to minimize damage to the kidney.”

The clinical benefits of Salient’s TRANSCOLLATION technology during partial nephrectomy procedures have been documented in nine published peer-reviewed articles. A bibliography of these studies is available at www.salientsurgical.com.

“Our goal is to help surgeons successfully perform partial nephrectomies whenever possible and maintain renal function in the remaining kidney,” said Joseph F. Army, President and CEO of Salient. “This is particularly beneficial to older patients and those suffering from conditions such as hypertension and diabetes. Introducing the AQUAMANTYS System to these procedures doubles the number of solid organ surgeries in which patients can be treated with TRANSCOLLATION technology.”

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. (www.salientsurgical.com) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION technology provides hemostatic sealing of soft tissue and bone, allowing surgeons to rapidly treat tissue at the surgical site to reduce blood loss and improve patient outcomes. Salient's products are currently used in orthopaedic reconstruction, spine surgery, brain tumor resection, trauma procedures and surgical oncology.

For further information contact:
Jennifer Silverman
Director, Marketing Communications
(603) 742-1515
jennifer.silverman@salientsurgical.com